Although multiple innovative treatments of inflammatory bowel disease have become available, research continues to refine the value of existing drug therapies for Crohn's disease and ulcerative colitis. What can Cochrane reviews tell us about evolving applications for traditional agents in inflammatory bowel disease? A Cochrane Collaboration symposium held at the 2014 Digestive Diseases Week annual meeting addressed this question. This article reviews the data presented at that session.
Article first published online 4 November 2015.
*Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, CA;
†Division of Gastroenterology, McMaster University, Hamilton, Ontario, CA;
‡Division of Gastroenterology, Departments of Medicine and Community Health Sciences, University of Calgary, Alberta, CA;
§Division of Gastroenterology, University of California San Diego, La Jolla, CA;
‖Robarts Clinical Trials, Inc, Robarts Research Institute, Western University, London, Ontario, CA;
Departments of ¶Medicine, and
**Epidemiology and Statistics, Western University, London, Ontario, CA.
Reprints: Brian G. Feagan, MD, Robarts Clinical Trials, Inc. Robarts Research Institute, Western University, 100 Perth Drive, London, Ontario N6A 5K8, Canada (e-mail: email@example.com).
See Acknowledgments for Author Disclosures.
Received August 13, 2015
Accepted September 14, 2015